LifeSci Capital analyst Sam Slutsky maintained a Buy rating on BELLUS Health (BLU – Research Report) on January 24 and set a price target of $17.00. The company’s shares closed last Wednesday at $5.90.
According to TipRanks.com, Slutsky is ranked 0 out of 5 stars with an average return of -4.8% and a 34.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $16.33 average price target, representing a 169.5% upside. In a report issued on January 25, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target.
The company has a one-year high of $9.84 and a one-year low of $2.60. Currently, BELLUS Health has an average volume of 3.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Read More on BLU: